Novo Nordisk NOVO.B-0.70%decrease ... shortly after Maziar Mike Doustdar took the reins and at a time the company behind ...

Sales of the drug have declined, eclipsed by soaring demand for Ozempic, which shares the same active ingredient ... All ...

COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug ... Sales of the drug have declined, ...

Multiple lawsuits have been filed against the makers of the popular weight-loss drug. Litigants cite blindness and other side-effects.

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.

Worker-led protests erupted at Microsoft headquarters this week as the tech company promises an “urgent” review of the ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Doustdar, a longtime company insider, took up the chief executive role on Aug. 7, a week after Novo Nordisk cut its outlook for the second time this year blaming competition from copycat versions of ...

As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

It faces more than 1,800 lawsuits consolidated in federal court in Pennsylvania and new claims emerging weekly, according to ...